NCT00122070View on ClinicalTrials.gov

Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

September 30, 2007

Study Completion Date

May 31, 2008

Conditions
Borderline Personality Disorder
Interventions
DRUG

Quetiapine Fumarate

Dosage can vary from 50 to 150 mg at PI's discretion

Trial Locations (1)

08002-2000

University of Medicine and Dentistry of New Jersey - School of Osteopathic Medicine - Department of Psychiatry, Cherry Hill

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University of Medicine and Dentistry of New Jersey

OTHER